Advertisement

Meda has entered into a promotion agreement with Mission Pharmacal, a company active in the women’s health area, for Meda’s topical estrogen replacement therapy product Elestrin.

Elestrin was acquired in 2012 from Jazz Pharmaceuticals and has showed good growth since then. Following the enhanced focus of Meda's US sales force on the allergy and respiratory area, the promotion agreement is a right step that will secure ongoing resources and continued growth for Elestrin.

"Through this partnership, we optimize sales efforts for Elestrin and at the same time increase our focus on the respiratory area", said Dr. Jörg-Thomas Dierks, CEO of Meda AB.

Advertisement
Advertisement